PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan. Electronic address: yohei@med.kobe-u.ac.jp.\', \'Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.\', \'Division of Infection Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.\', \'R&D, Cellspect Co., Ltd., Morioka, Japan.\', \'Division of Gastrointestinal Surgery, Department of Surgery, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.\', \'Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan; Cancer Center, Kobe University Hospital, Kobe, Japan.\', \'Division of Urology, Department of Surgery, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.\', \'Division of Thoracic Surgery, Department of Surgery, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.\', \'Division of Clinical Virology, Center for Infectious Diseases, Kobe University, Graduate School of Medicine, Kobe, Japan.\']
?:citedBy
  • -1
?:creator
?:doi
  • S1341-321X(21)00357-310.1016/j.jiac.2021.12.021
?:doi
?:hasPublicationType
?:journal
  • Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
is ?:pmid of
?:pmid
?:pmid
  • 35090826
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all